A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial.

A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial.

Show other versions (1)

OBJECTIVE: To study the immunogenicity and reactogenicity of a combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine (Hib-MenC-TT) when administered as a booster dose in combination with a measles, mumps and rubella vaccine (MMR). DESIGN: A p...

Full description

Bibliographic Details
Main Authors:	Pace, D, Snape, M, Westcar, S, Oluwalana, C, Yu, L, Begg, N, Wysocki, J, Czajka, H, Maechler, G, Boutriau, D, Pollard, A
Format:	Journal article
Language:	English
Published:	2008

Similar Items

A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial
by: Pace, D, et al.
Published: (2008)

Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study.
by: Khatami, A, et al.
Published: (2012)

Phase II study of a three-dose primary vaccination course of DTPa-IPV/Hib-MenC-TT followed by a 12-month Hib-MenC-TT booster in healthy infants.
by: Khatami, A, et al.
Published: (2013)

A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants.
by: Pace, D, et al.
Published: (2007)

Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial.
by: Khatami, A, et al.
Published: (2011)

Serogroup C meningococci in Italy in the era of conjugate menC vaccination
by: Neri Arianna, et al.
Published: (2009-08-01)

Bactericidal antibodies against hypervirulent Neisseria meningitidis C field strains following MenC-CRM or MenACWY-CRM priming and MenACWY-CRM booster in children
by: Marzia Monica Giuliani, et al.
Published: (2021-05-01)

Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children
by: Markus Knuf, et al.
Published: (2012-07-01)

Modelling the Public Health Impact of MenACWY and MenC Adolescent Vaccination Strategies in Germany
by: Sebastian Gruhn, et al.
Published: (2024-04-01)

Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy
by: Pace, D, et al.
Published: (2016)

Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine
by: De Whalley, P, et al.
Published: (2011)

Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
by: de Whalley, P, et al.
Published: (2011)

The invasive Neisseria meningitidis MenC CC103 from Brazil is characterized by an accessory gene repertoire
by: Michel Abanto Marin, et al.
Published: (2017-05-01)

Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization.
by: Snape, MD, et al.
Published: (2006)

Serogroup c meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization
by: Snape, M, et al.
Published: (2006)

A phase II, randomized study on an investigational DTPw-HBV/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana.
by: Abraham Hodgson, et al.
Published: (2008-01-01)

DTaP5-IPV-Hib-HepB, a hexavalent vaccine for infants and toddlers
by: Andrew W. Lee, et al.
Published: (2017-02-01)

When Shakespeare met Raimi: David Mence’s Macbeth re-arisen
by: Ruben Benatti, et al.
Published: (2017-11-01)

Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine.
by: Snape, MD, et al.
Published: (2009)

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
by: Snape, MD, et al.
Published: (2008)

The antibody response following a booster with either a 10- or 13-valent pneumococcal conjugate vaccine in toddlers primed with a 13-valent pneumococcal conjugate vaccine in early infancy.
by: Trück, J, et al.
Published: (2016)

Primary and booster vaccination in Latin American children with a DTPw-HBV/Hib combination: a randomized controlled trial
by: Collard Alix, et al.
Published: (2010-10-01)

Recent advances in lipopolysaccharide-based glycoconjugate vaccines
by: Zhu, H, et al.
Published: (2021)

Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1-10 Years of Age
by: Timo Vesikari, et al.
Published: (2020-06-01)

Immunogenicity and Reactogenicity of DTPa-IPV/Hib Vaccine Co-administered With Hepatitis B Vaccine for Primary and Booster Vaccination of Taiwanese Infants
by: Pei-Lan Shao, et al.
Published: (2011-06-01)

Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
by: Perrett, K, et al.
Published: (2009)

Safety and Immunogenicity of Heptavalent Pneumococcal Conjugate Vaccine Booster in Taiwanese Toddlers
by: Pei-Lan Shao, et al.
Published: (2006-01-01)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study
by: Timo Vesikari, et al.
Published: (2020-06-01)

Bayesian Estimation of Latent Space Item Response Models with <tt>JAGS</tt>, <tt>Stan</tt>, and <tt>NIMBLE</tt> in <tt>R</tt>
by: Jinwen Luo, et al.
Published: (2023-05-01)

Influence of genetic and environmental factors on the immunogenicity of Hib vaccine in Gambian twins.
by: Lee, Y, et al.
Published: (2006)

The B-cell response to a primary and booster course of MenACWY-CRM₁₉₇ vaccine administered at 2, 4 and 12 months of age.
by: Blanchard-Rohner, G, et al.
Published: (2013)

Glycoconjugates in host-helminth interactions
by: Nina Salinger Prasanphanich, et al.
Published: (2013-08-01)

Influence of genetic and environmental factors on the immunogenicity of Hib vaccine in Gambian twins
by: Lee, Y, et al.
Published: (2006)

Recent developments in glycoconjugates
by: Davis, B
Published: (1999)

Real-world impact and effectiveness of MenACWY-TT
by: Rodolfo Villena, et al.
Published: (2023-08-01)

The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age
by: Blanchard-Rohner, G, et al.
Published: (2013)

Highly selective trimerisation of MeNC by a novel titanium imido complex containing a tridentate dianionic ligand
by: Blake, A, et al.
Published: (1997)

Occurrence of Haemophilus influenzae type b (Hib) meningitis in a 2 month-old infant in the Hib vaccination era
by: Yoshiaki Cho, et al.
Published: (2022-06-01)

A randomized, open-label clinical trial to evaluate immunogenicity and safety of an indigenously developed DTwP-Hib tetravalent combination vaccine (Easyfour®-TT) with Quadrovax® in Indian infants
by: Lalitendu Mohanty, et al.
Published: (2017-09-01)

Exploring and exploiting the therapeutic potential of glycoconjugates.
by: Doores, K, et al.
Published: (2006)